Ranolazine dihydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种抗缺血剂，已被证明可以抑制晚期 I(Na) 和 I(Kr)，并在各种临床前体外模型中具有抗心律失常作用。

An anti-ischemic agent that has been shown to inhibit late I(Na) and I(Kr) and to have antiarrhythmic effects in various preclinical in vitro models; also inhibits cardiac sodium channel Nav1.5, shows antiarrhythmic, antiepileptic, and analgesic effects.Other Indication Approved(In Vivo):Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

——

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion. Animal Model:Male Wistar rats (240-350 g) Dosage:Bolus injection 10 mg/kg and infusion (9.6 mg/kg/h) Administration:Bolus injection; for 145 minutes Result: Significantly reduced infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

RS-43285

Membrane Transporter/Ion Channel

Sodium Channel

CalciumChannel|SodiumChannel

Other Indications

Other Disease

95635-56-6

500.4584

C24H35Cl2N3O4

>98% (HPLC)

10 mM in DMSO

Cl.Cl.COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1

1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, hydrochloride (1:2)

(-20℃)

With Ice Pack

≥ 2 years